BioCentury

8:00 AM GMT, Jan 1, 2007
This article and the information contained in BioCentury's publications and services are solely for your own personal, non-transferable licensed use and cannot be shared with any other individuals. For information about adding subscribers to your account or obtaining article reprints, please contact support@biocentury.com.
Analyst Picks & Changes

Analyst picks & changes

Analyst picks & changes

Analyst picks & changes
Company Bank Analyst Coverage Opinion Wk chg 12/29 cls
Advancis (AVNC) Merriman Curhan Ford Brian McCarthy New Buy 10% $3.91
McCarthy said FDA approval of Amoxicillin Pulsys could drive the stock to the $12-$15 range. Last month, AVNC submitted an NDA for once-daily use of the pulsatile-release formulation of amoxicillin to treat adolescents and adults with pharyngitis/tonsillitis (strep throat). McCarthy expects approval in 4Q07.
Avalon (AVRX) Rodman Ren Benjamin New Market outperform 5% $3.90
Benjamin set a $10 target. He

Read the full 887 word article

This article and the information contained in BioCentury's publications and services are solely for your own personal, non-transferable licensed use and cannot be shared with any other individuals. For information about adding subscribers to your account or obtaining article reprints, please contact support@biocentury.com.